Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

Contact Supplier

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

DIGITAL CONTENT

3 News #PharmaBuzz

media
3 News #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

12DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Regulatory FDF Prices

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

API

FDF

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Glecirasib, Kras g12c inhibitor 62, Glecirasib [inn], Up75wh4qkm, Schembl23830094, Ex-a8185q

Molecular Formula

C₃₁H₂₆ClF₄N₇O₂

Molecular Weight

640.0 g/mol

InChI Key

QRRJEUIQLZNPIO-UHFFFAOYSA-N

FDA UNII

UP75WH4QKM

Glecirasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, glecirasib selectively targets, binds to and inhibits the activity of the KRAS G12C mutant, thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

1 2D Structure

Glecirasib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile

2.1.2 InChI

InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3

2.1.3 InChI Key

QRRJEUIQLZNPIO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N

2.2 Other Identifiers

2.2.1 UNII

UP75WH4QKM

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Glecirasib

2. Kras G12c Inhibitor 62

3. Glecirasib [inn]

4. Up75wh4qkm

5. Schembl23830094

6. Ex-a8185q

7. Hy-143589

8. Hy-157067

9. Cs-0373885

10. Cs-0904896

11. 2657613-87-9

12. 2658588-10-2

2.4 Create Date

2021-12-03

3 Chemical and Physical Properties

Molecular Formula	C₃₁H₂₆ClF₄N₇O₂
Molecular Weight	640.0 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	5
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	119
Heavy Atom Count	45
Formal Charge	0
Complexity	1240
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1